Safety Study of Abatacept in Sweden

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01094795

IM101-125

Details and patient eligibility

About

The primary purpose of this study is to assess incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept.

Enrollment: 92,635 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Resident of Sweden

Exclusion criteria

• None

Trial design

92,635 participants in 5 patient groups

Patients initiating abatacept

Patients receiving other biologic disease-modifying drugs

Patients with early rheumatoid arthritis (RA)

Patients with prevalent RA identified by hospitalization

General population